Neo-Healer: what clinicians are saying
anbenitamab plus HB1801 in early or locally advanced HER2-positive breast cancer · NCT06747338 ↗ · Phase 3 · Shanghai JMT-Bio Inc.
A medical oncologist thinks Neo-Healer could change treatment because of its response gain, but still awaits survival results. Another speaker sees potential for use in Asia while seeking evidence of applicability to other ethnicities. Medical oncologists question how much of the gain reflects HER2 blockade rather than nab-docetaxel; one also requires independent development and Western validation before adoption.
Created with AI · how we check it
- edition 1
- commentary checked Nov 20, 2026
- 104 verified statements
This edition $750, with MCP access for your AI agent. Get this report
10 findings, and what sits behind each
01. Neo-Healer: some speakers want more data; some see practice-change potential
4 of the report's 7 cited clinicians · 22 statements from 10 speakers in 14 sources, 1 of them a podcast or video · 21 passages
Limitations recorded: 4.
Draws on: Primary endpoint: tpCR (BIRC, AJCC 8th), Secondary endpoints, Population and setting, Safety and tolerability, The comparison.
02. HER2 targeting: most speakers question attribution; some clinicians see possible gains
6 of the report's 7 cited clinicians · 22 statements from 7 speakers in 11 sources, 2 of them podcasts or videos · 34 passages
Limitations recorded: 3.
Draws on: The comparison, Design and conduct, Primary endpoint: tpCR (BIRC, AJCC 8th), Secondary endpoints, Population and setting, Safety and tolerability.
03. Carboplatin: what speakers say
No named clinician · accounts and unnamed speakers · 15 statements from 3 speakers in 5 sources, 1 of them a podcast or video · 21 passages
Limitations recorded: 2.
Draws on: Primary endpoint: tpCR (BIRC, AJCC 8th), Population and setting, Design and conduct, The comparison, Safety and tolerability.
04. Neo-Healer: most speakers cite AE rates; one weighs a shorter non-ADC course
2 of the report's 7 cited clinicians · 11 statements from 5 speakers in 7 sources, 1 of them a podcast or video · 11 passages
Limitations recorded: 3.
Draws on: Safety and tolerability, Primary endpoint: tpCR (BIRC, AJCC 8th), The comparison, Secondary endpoints, Population and setting.
05. Neo-Healer/DB11: what speakers say
No named clinician · accounts and unnamed speakers · 9 statements from 2 speakers in 4 sources, 1 of them a podcast or video · 13 passages
Limitations recorded: 4.
Draws on: The comparison, Population and setting, Safety and tolerability.
06. Beyond China: some speakers seek validation; one questions Western access
1 of the report's 7 cited clinicians · 12 statements from 4 speakers in 9 sources, 2 of them podcasts or videos · 13 passages
Limitations recorded: 4.
Draws on: Population and setting, Design and conduct, Secondary endpoints, The comparison.
07. Payload-free backbone: a speaker asks if it could reserve T-DXd for residual disease
No named clinician · accounts and unnamed speakers · 4 statements from 1 speaker in 2 sources · 2 passages
Limitations recorded: 3.
08. Regimen: a speaker risk-adapts; one wants long-term T-DXd data
No named clinician · accounts and unnamed speakers · 10 statements in 1 source, a podcast or video · 16 passages
Limitations recorded: 3.
Draws on: Population and setting.
Beyond the trial population
09. T-DXd×4: a speaker awaits RFS/OS; one leans on other evidence
No named clinician · accounts and unnamed speakers · 8 statements in 1 source, a podcast or video · 11 passages
Limitations recorded: 3.
10. Neo-Healer: a clinician sees a possible GI preview; one notes HER2 advances
1 of the report's 7 cited clinicians · 2 statements from 1 speaker in 2 sources, 1 of them a podcast or video · 2 passages
Limitations recorded: 2.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 10
4 of the report's 7 cited clinicians
Neo-Healer: some speakers want more data; some see practice-change potential
22 statements from 10 speakers in 14 sources, 1 of them a podcast or video
5 of the 10 named speakers in this finding hold this view; 3 of the 10 hold its caveat, “some see practice-change potential”
- 22
- statements
- 21
- passages
- 14
- sources
- 10
- speakers
What the statements areViews 13Questions and uncertainty 2Clinical experience 0Comparisons 0Restated results and context 7Statement-to-passage links (a passage can back several statements)Supporting a statement 25Giving context 3Recorded with the findingLimitations: 4
12 posts and articles · 1 podcast or video · 1 publication
Draws on: Primary endpoint: tpCR (BIRC, AJCC 8th), Secondary endpoints, Population and setting, Safety and tolerability, The comparison.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
2 of the 10 findings and 7 of the 104 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (10)
AE, adverse event; EFS, event-free survival; GI, gastrointestinal; HCP, healthcare professional; HER2, human epidermal growth factor receptor 2; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; OS, overall survival; RFS, relapse-free survival; T-DXd, trastuzumab deruxtecan.
The full Neo-Healer report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians say they need to see on EFS/OS, the contribution of different taxanes and Western validation before considering neoadjuvant anbenitamab plus HB1801, with or without carboplatin, a new standard for stage II–III HER2-positive breast cancer?
From finding F1 (22 statements from 10 speakers in 14 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 43commentary sources screened
- 22sources cited by verified statements
- 16named in screened sources
- 16speakers cited in the report
- 15cited speakers with a verified identity
7 cited clinicians, speakers with a confirmed clinical role, of them 7 physicians. By role and specialty:
- 6 physician, Medical oncology
- 1 physician, specialty not confirmed
Also in the sources: 4 organizational or shared accounts, not counted as people.
- 104verified statements, each linked to its source
- 13of them from speakers with a confirmed clinical role
- 10findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 10 | Titles free |
| Detailed analysis | 12 sections | Paid |
| Verified statements with short source quotes and links | 104 | Paid |
| Who said each statement: the cited speakers | 16 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 7 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 15 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 11 | Free |
| Sources with links | 22 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
11 discussed · 0 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: tpCR (BIRC, AJCC 8th) | 20 | 15 |
| Secondary endpoints | 10 | 7 |
| Population and setting | 16 | 9 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 29 | 12 |
| Safety and tolerability | 9 | 7 |
| Design and conduct | 12 | 7 |
| Mechanistic promise and component attribution | 14 | 7 |
| Carboplatin omission and individualized use | 14 | 4 |
| Reception, adoption thresholds and access | 24 | 17 |
| DESTINY-Breast11 comparisons and residual-disease strategy | 22 | 3 |
| Wider HER2 development perspective | 2 | 2 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
104 verified statements from 22 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 44 statements · 42% | ||||
| YouTube | 44 | 3 | 4 | |
| Posts · 39 statements · 38% | ||||
| X threads | 32 | 16 | 36 | |
| LinkedIn posts | 7 | 2 | 2 | |
| Bluesky threads | 0 | 0 | 1 | |
| Primary sources · 21 statements · 20%cited for context, not screened | ||||
| Publications | 21 | 1 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 28 / quarter
- Screened window
- Apr 1, 2026 → Nov 5, 2026
- Cited window
- Apr 1, 2026 → Nov 5, 2026
- Retrieved
- Nov 20, 2026
The trial
from ClinicalTrials.gov- Title
- A Randomized, Controlled, Open-label, Multicenter, Phase III Clinical Trial to Compare the Efficacy and Safety of KN026 Combined With HB1801 ± Carboplatin Versus Trastuzumab Combined With Pertuzumab and Docetaxel ± Carboplatin in Neoadjuvant Treatment of Early or Locally Advanced HER2-positive Breast Cancer.
- Registry
- NCT06747338
- Study IDs
- KN026-004
- Sponsor
- Shanghai JMT-Bio Inc.
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Active, not recruiting
- Enrollment
- 520 estimated
- Registered
- 2024-12-24
- Start
- 2024-12-16 actual
- Primary completion
- 2026-12-16 estimated
- Primary endpoint
- tpCR (BIRC, AJCC 8th)
- Interventions
- 6 registered
More on: Breast cancer, anbenitamab
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 1 matching source (1 X thread) could not be read and is not included.
- 43 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 18 sources about other trials or topics are not included.
- The sources reviewed do not establish the prevalence of any view among HCPs, and source counts or reposts cannot be treated as independent clinician endorsement.
Show all 12 known gaps +Fewer −
- Several video statements cannot be assigned to a named speaker. Publisher participant lists and professional profiles do not establish who made those statements.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Relevant discussion may be missing when it never names the trial, uses unexpected spelling or addresses the same treatment decision without recognizable study terminology. One additional X conversation could not be assessed.
- No separate protocol was available. The regulatory material reviewed was incomplete, and no exact KN026 or HB1801 label was located; the report does not establish comprehensive approval or availability status.
- Early endpoint-announcement reactions, later numerical-result commentary and subsequent panel recollections have different information contexts. Their dates do not establish a change of mind.
- Cross-study pCR and toxicity comparisons do not establish comparative superiority. The sources’ population, comparator and exposure-duration qualifications remain essential.
- The unexplained negative reply and the unspecified questions relayed from a discussant cannot support more specific objections than the text provides.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 20, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. Neo-Healer (NCT06747338): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 20, 2026. https://www.erudio.com/reports/neo-healer-nct06747338
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "Neo-Healer" (NCT06747338), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "neo-healer-nct06747338". If you cannot make requests, read https://www.erudio.com/reports/neo-healer-nct06747338.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT06747338", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT06747338 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/neo-healer-nct06747338.json
curl https://www.erudio.com/reports/neo-healer-nct06747338.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "neo-healer-nct06747338" })release f1f08e42df26e2c2ed6bb58ce7e7fc941a0b89ca6050a9d2498b4880318dd7f9
Questions
How much does the Neo-Healer report cost?
One edition costs $750 (Focused · 104 verified statements · 13 from 7 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the Neo-Healer report cover?
104 statements from 22 sources (3 videos, 18 posts, 1 paper), 13 of them from 7 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the Neo-Healer report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "neo-healer-nct06747338" }) previews it and create_order({ "report": "neo-healer-nct06747338", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the Neo-Healer report?
Edition 1 (version 1.0.0), accepted Nov 20, 2026 UTC; last checked for new commentary Nov 20, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.